0000950170-23-069496.txt : 20231211 0000950170-23-069496.hdr.sgml : 20231211 20231211200003 ACCESSION NUMBER: 0000950170-23-069496 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231211 FILED AS OF DATE: 20231211 DATE AS OF CHANGE: 20231211 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Astle Christopher CENTRAL INDEX KEY: 0001915257 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41535 FILM NUMBER: 231479729 MAIL ADDRESS: STREET 1: 114 EAST 4TH AVENUE, SUITE 800 CITY: VANCOUVER STATE: A1 ZIP: V5T 1G4 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Zymeworks Inc. CENTRAL INDEX KEY: 0001937653 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 108 PATRIOT DRIVE, SUITE A CITY: MIDDLETOWN STATE: DE ZIP: 19709 BUSINESS PHONE: 206-337-1030 MAIL ADDRESS: STREET 1: 108 PATRIOT DRIVE, SUITE A CITY: MIDDLETOWN STATE: DE ZIP: 19709 FORMER COMPANY: FORMER CONFORMED NAME: Zymeworks Delaware Inc. DATE OF NAME CHANGE: 20220712 4 1 ownership.xml 4 X0508 4 2023-12-11 0001937653 Zymeworks Inc. ZYME 0001915257 Astle Christopher C/O ZYMEWORKS INC. 108 PATRIOT DRIVE, SUITE A MIDDLETOWN DE 19709 false true false false SVP & Chief Financial Officer false Common Stock 2023-12-11 4 M false 1550 0.00 A 2883 D Common Stock 2023-12-11 4 S false 886 9.1301 D 1997 D Restricted Stock Unit 2023-12-11 4 M false 1550 0.00 D Common Stock 1550 0 D Represents shares of common stock issued upon vesting of one half of the restricted stock units ("RSUs") granted on December 10, 2021. Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs pursuant to mandatory "sell to cover" provisions contained in the Reporting Person's applicable RSU grant agreement, and does not represent a discretionary sale by the Reporting Person. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.11 to $9.16, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The RSUs were granted on December 10, 2021 and vested in two equal annual instalments (on December 12, 2022 and December 11, 2023). /s/ Daniel Dex, Attorney-in-Fact 2023-12-11